Steadymed LTD. – Ordinary Shares (NASDAQ:STDY) Shorts Decreased By 7.28% As Of Jun 26, 2018

June 26, 2018 - By Matthew Medley

SteadyMed Ltd. (NASDAQ:STDY) Corporate Logo

Steadymed LTD. – Ordinary Shares (NASDAQ:STDY) had a decrease of its short interest by 7.28%. FINRA announced short interest of STDY’s total 52,200 shares. Previously was reported down change of 7.28% from 56,300 shares. Former STDY’s position will need 0 days to restore. It has 144,700 average volume. 0.45% is Steadymed LTD. – Ordinary Shares float short.

The last price was $4.55.Since June 26, 2017 it’s 34.29% down thus downtrending. The stock underperformed the S&P500 by 46.86%.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs.The firm is worth $120.91 million. The company??s product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology.Currently it has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Coverage

Total analysts of 2 have positions in Steadymed (NASDAQ:STDY) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since January 10, 2018 according to StockzIntelligence Inc Steadymed has 3 analyst reports. On Monday, April 9 H.C. Wainwright maintained SteadyMed Ltd. (NASDAQ:STDY) rating. H.C. Wainwright has “Buy” rating and $1500 target. On Tuesday, May 1 JMP Securities downgraded the shares of STDY in report to “Market Perform” rating.

SteadyMed Ltd. (NASDAQ:STDY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.